Sequence-dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action

Sorafenib (Nexavar, BAY43-9006 or Sora) is the first molecular targeted agent that has exhibited significant therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond well to Sora and novel therapeutic strategies to optimize the efficacy of Sora are urgen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahman, Abdulmajeed A., Abaza, Mohamed Salah I., Khoushiash, Sarah I., Al-Attiyah, Rajaa J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089756/
https://www.ncbi.nlm.nih.gov/pubmed/29901131
http://dx.doi.org/10.3892/ijmm.2018.3725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089756/
https://www.ncbi.nlm.nih.gov/pubmed/29901131
http://dx.doi.org/10.3892/ijmm.2018.3725

Ejemplares similares